GlassScriptPhysician profile
Jennifer L Jordan
NPI 1891185674
$7,161.78
in general payments reported to CMS, 2019-2025
29 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $795 · 2022: $1,097 · 2023: $2,745 · 2024: $2,413 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,173 · Education: $96.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,172.64 |
| Education | $96.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,361.75 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $481.06 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $476.05 | 2021-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $448.22 | 2022-2024 | Farxiga |
| Novo Nordisk INC | $436.59 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $425.69 | 2021-2025 | Descovy, Biktarvy |
| Lilly USA, LLC | $413.96 | 2021-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $315.37 | 2023-2024 | |
| Antares Pharma, INC. | $270.62 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $266.14 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.29 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $194.13 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $125.85 | 2022-2024 | |
| Halozyme INC | $106.52 | 2023 | |
| Astellas Pharma US INC | $90.00 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $75.22 | 2023-2024 | Camzyos |
| Amarin Pharma, INC. | $71.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.88 | 2021-2024 | Xifaxan |
| Amgen INC. | $41.21 | 2023-2024 | Aimovig, Repatha, Otezla |
| Smith+Nephew, INC. | $40.86 | 2022 | |
| Allergan, INC. | $35.20 | 2021 | |
| Glaxosmithkline, LLC. | $33.39 | 2024 | Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $28.23 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.55 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $23.27 | 2021 | |
| Merck Sharp & Dohme LLC | $22.28 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Idorsia Pharmaceuticals US INC | $22.22 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $16.03 | 2022 | |
| Aroa Biosurgery Incorporated | $13.52 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.